Latest News about IONS
Recent news which mentions IONS
Tickers
IONS
From InvestorPlace
Genetic Medicines Focused-Ionis Pharmaceuticals' Fatty Liver Candidate Lowers Excess Liver Fat, Midstage Study Data Shows
March 13, 2024
From Benzinga
Earnings Scheduled For February 21, 2024
February 21, 2024
From Benzinga
JP Morgan Maintains Neutral Rating for Ionis Pharmaceuticals: Here's What You Need To Know
February 01, 2024
Tickers
IONS
From Benzinga
Biogen Gives Up On Aduhelm Efforts After Two Years Of Controversial FDA Accelerated Approval For Alzheimer's, Shifts Focus On Newer Medicines
January 31, 2024
From Benzinga
Rare Disease Focused Ionis Pharmaceuticals Gears Up for FDA Submission After Donidalorsen Outperforms Placebo In Swollen Vessels Study
January 22, 2024
From Benzinga
Expert Outlook: Ionis Pharmaceuticals Through The Eyes Of 8 Analysts
January 18, 2024
Tickers
IONS
From Benzinga
2024 And Beyond – Exploring Six Investment Megatrends With Tema ETFs
January 04, 2024
From Benzinga
10 Health Care Stocks Whale Activity In Today's Session
January 02, 2024
From Benzinga
From InvestorPlace
Pricing Projections And Market Potential For Ionis' Newly Approved Nerve Damage Drug - Analyst Sees Over $700M Potential
December 22, 2023
From Benzinga
New Hope for Nerve Damage Patients as AstraZeneca/Ionis' Eplontersen Receives FDA Nod for Hereditary Amyloidosis Treatment
December 22, 2023
From Benzinga
From Benzinga
Cathie Wood's Ark Invest Goes Shopping For Moderna Stock — Sells DraftKings Shares Amid Quarterly Rise In Revenue, EPS Beat
November 02, 2023
From Benzinga
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2023
September 29, 2023
From Benzinga
Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges
September 27, 2023
From Benzinga
Analyst Expectations for Ionis Pharmaceuticals's Future
September 27, 2023
Tickers
IONS
From Benzinga
Ionis Pharmaceuticals' Rare Metabolic Disorder Candidate Poised To Become New Standard Treatment, Study Shows Encouraging Action
September 26, 2023
Tickers
IONS
From Benzinga
The 7 Most Hated Stocks by Institutional Traders
September 20, 2023
From InvestorPlace
Hypertension Impacts 1.2B People - Alnylam's Gene Silencing Drug Candidate Hits the Mark in Phase 2 Study, Offering Hope
September 07, 2023
From Benzinga
Cathie Wood Buys Shares Of Pacific Biosciences, Reduces Exposure To DraftKings And Genius Sports
August 07, 2023
From Benzinga
From Benzinga
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.